Gamida reduces its workforce by 17% and abandons NK cell therapy research
More than a year after reducing its workforce, Gamida Cell has resorted to layoffs to keep its long-delayed plans for its blood cancer treatment omidubicel on track. Last November, the FDA revealed that it was unlikely to make an approval decision before May 1, three months later than previously predicted. According to a full-year earnings … Read more